NEW YORK (Reuters) -- An investment fund controlled by billionaire investor George Soros said Friday it did not have any inside information when it sold $24 million worth of Auxilium Pharmaceuticals Inc. shares a day before the company announced problems with a key clinical trial.
"We were not in possession of any material, non-public information at the time of the trade," the Perseus-Soros Biopharmaceutical Fund said in a statement.
Monday, December 11, 2006
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment